Contravisory Investment Management’s Vornado Realty Trust VNO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-400
Closed -$15.3K 427
2025
Q2
$15.3K Hold
400
﹤0.01% 323
2025
Q1
$14.8K Sell
400
-216
-35% -$8.69K ﹤0.01% 327
2024
Q4
$25.9K Sell
616
-98
-14% -$4.14K 0.01% 260
2024
Q3
$28.1K Hold
714
0.01% 250
2024
Q2
$18.8K Sell
714
-224
-24% -$5.73K ﹤0.01% 277
2024
Q1
$27K Hold
938
0.01% 271
2023
Q4
$26.5K Buy
+938
New +$22.3K 0.01% 239
2021
Q4
Sell
-11,290
Closed -$474K 324
2021
Q3
$474K Buy
11,290
+42
+0.4% +$1.81K 0.14% 86
2021
Q2
$525K Buy
11,248
+10,133
+909% +$474K 0.15% 77
2021
Q1
$51K Buy
+1,115
New +$46.2K 0.02% 220
2015
Q3
Sell
-124,223
Closed -$9.53M 181
2015
Q2
$9.53M Sell
124,223
-6,498
-5% -$539K 2.07% 27
2015
Q1
$11.8M Sell
130,721
-13,620
-9% -$1.22M 2.38% 19
2014
Q4
$12.4M Sell
144,341
-1,796
-1% -$144K 2.51% 18
2014
Q3
$10.7M Buy
+146,137
New +$11.3M 2.23% 27

Other funds holding VNO

Contravisory Investment Management's VNO Position: Q3 2025 in Review

Contravisory Investment Management sold out of Vornado Realty Trust (VNO) in Q3 2025, closing a stake of 400 shares — an estimated $15.3K sold.

Contravisory Investment Management first reported a position in VNO in Q3 2014 and held it in 14 quarters. The position peaked at $12.4M in Q4 2014. 399 funds tracked by Wall St. Rank hold VNO as of Q3 2025.

  • Contravisory Investment Management reported no remaining Vornado Realty Trust position as of Q3 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 400 Vornado Realty Trust shares in Q3 2025, an estimated $15.3K.
  • Contravisory Investment Management first reported a position in Vornado Realty Trust in Q3 2014 and held it in 14 quarters.
  • Contravisory Investment Management's Vornado Realty Trust position peaked at $12.4M in Q4 2014.
  • 399 funds tracked by Wall St. Rank held Vornado Realty Trust as of Q3 2025.

Based on Contravisory Investment Management's 13F filing for Q3 2025, filed 9 Oct 2025.